Zydus Lifesciences venture capital arm injects in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-03-13 06:00 GMT | Update On 2025-03-13 06:47 GMT

Pennington: Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences, has announced its investment in Illexcor Therapeutics, a biopharmaceutical company developing next-generation oral therapies for sickle cell disease(SCD).

Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD. Their lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits.

Speaking on the development, Dr. Sharvil Patel, MD of Zydus Lifesciences, said, “This investment reflects our commitment to patients battling rare and orphan diseases. Recognizing the profound impact of sickle cell disease on patients' lives, we are pleased to support Illexcor in their efforts to develop a novel therapeutic solution addressing this critical unmet medical need.”

Emphasizing the strategic significance of the investment, Jay Kothari, Director of Zynext Ventures said, “This investment is consistent with Zynext Ventures' objective of identifying and fostering transformative early-stage healthcare innovations. Beyond the financial backing, Zynext Ventures will leverage its unique data analytics and strategic expertise to accelerate Illexcor's path to delivering this potentially life-changing therapy globally.”

Andrew Fleischman, CEO of Illexcor stated, “We are excited to partner with Zynext Ventures to advance our lead drug ILX002 into clinical trials later this year. We are hopeful that ILX002 will be a transformative treatment not only for SCD patients in the U.S. but also for millions around the globe. Zynext Ventures and Zydus Lifesciences are in a strategic position to help us achieve these goals.”

Sickle cell disease is a devastating and debilitating genetic condition that affects up to 10 million people worldwide. The disease continues to severely impact quality of life and longevity. Highly efficacious oral drug therapies are urgently needed to manage this condition on a global scale.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Lifesciences venture capital arm injects in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Similar News

Advent to Sell Zentiva to Private Equity GTCR in USD 4.8 Billion Deal, Closing Expected in 2026

Chennai Court Acquits 2 After Alleged Nitravet Haul Found to Be Paracetamol

USFDA warns pharma cos to remove misleading ads

Intas Pharma appoints Dr Ajay Kumar Handa as new Executive Vice President - RnD

Sun Pharma Halol facility gets OAI status from USFDA

Sanofi gets USFDA fast track designation for neovascular age-related macular degeneration gene therapy

Braille Labels, QR Code Voice Assistance on Drugs? CDSCO Seeks Stakeholder Comments

Tata Elxsi inaugrates Bayer Development Centre in Radiology at Pune